Elevation Oncology, Inc. (NasdaqCM: ELEV)
Health Care · Biotechnology · US
$—
— today · — 1Y
Elevation Oncology, Inc. (NasdaqCM: ELEV) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores Elevation Oncology, Inc. across four factors: quality 36/100, value 56/100. Its strongest factor is value.
ELEV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.81
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 34
- Next earnings
- —
About Elevation Oncology, Inc.
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion. The company was established in 2019 and is headquartered in New York, New York.
- ISIN
- US28623U1016
- Founded
- 2019
- Listed since
- Jun 25, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PhaseRx, Inc.OTCPK: PZRX.Q | $12.00 | $— | — |
| ContraFect CorporationOTCPK: CFRX.Q | $11.00 | $0.00 | — |
| Notable Labs, Ltd.OTCPK: NTBL.Q | $10.00 | $— | — |
| OncoSec Medical IncorporatedOTCPK: ONCS.Q | $6.00 | $0.00 | — |
| Calithera Biosciences, Inc.OTCPK: CALA | $5.00 | $0.00 | -99.00% |
| Biocept, Inc.OTCPK: BIOC.Q | $3.00 | $0.00 | -99.50% |
| Yield10 Bioscience, Inc.OTCPK: YTEN.Q | $1.00 | $— | — |
| LadRx CorporationOTCPK: LADX | $0.00 | $0.00 | -99.50% |
Figures last refreshed Oct 18, 2026.